• TUNEL Assays for Translational Apoptosis Research

  2026-08-14

  A mechanistic and strategic guide to using TUNEL-based DNA fragmentation analysis in tissue and cell models, with lessons from spinal cord injury research and practical guidance for building more reproducible translational apoptosis workflows.

• Lysosomal Exocytosis in MPS IVA Cartilage Pathology

  2026-08-13

  A 2026 study in Disease Models & Mechanisms identifies enhanced lysosomal exocytosis as a feature of cartilage pathology in galns-mutant zebrafish, while showing that its downstream effects differ from those reported in sialidosis. The findings connect lysosome trafficking, cathepsin activity, glycosaminoglycan distribution and TGFβ/BMP signaling, providing a more nuanced framework for studying skeletal lysosomal storage disorders.

• O/F-Fc Nanosheets Remodel Tumor Microenvironments

  2026-08-13

  A 2026 ACS Nano study introduces a premix–dropwise–stir strategy for producing carrier-free oleanolic acid/perfluorocarbon-ferrocene nanosheets that combine oxygen delivery, Fenton-like chemodynamic therapy, reactive species amplification, and tumor microenvironment remodeling. The findings suggest that integrating structural control with antifibrotic and immunomodulatory functions can improve the activity and tissue penetration of ferrocene-based nanosystems.

• Ferrostatin-1 for Rigorous Ferroptosis Assays

  2026-08-12

  Ferrostatin-1 (Fer-1) provides a practical rescue strategy for distinguishing ferroptosis from nonspecific cytotoxicity in cancer, neuronal, and ischemic models. This guide translates ovarian cancer findings into assay design, control selection, product handling, and troubleshooting steps.

• Multiple Myeloma Cell Lines: Mutations and Drug Response

  2026-08-12

  Vikova and colleagues provide a comprehensive whole-exome analysis of 30 human multiple myeloma cell lines, identifying established and previously underappreciated mutations linked to oncogenic pathways and drug response. The study offers a practical framework for selecting genetically appropriate models while emphasizing that cell-line associations require validation in primary disease systems.

• SepM Mutations in S. mutans Clinical Isolates

  2026-08-11

  Liu et al. investigated how naturally occurring sepM mutations in Streptococcus mutans clinical isolates influence antagonism toward Streptococcus gordonii. Their combination of clinical isolate genotyping, expression analysis, recombinant protein studies, and CSP-21 binding measurements linked selected missense variants to stronger, pH-dependent SepM–CSP-21 interactions.

• JXY, TLR4, and M1 Polarization in Colitis-Associated CRC

  2026-08-11

  Liu et al. show that Jiedu Xiaozheng Yin (JXY) limits colitis-associated colorectal cancer progression in mice while shifting intestinal macrophages toward an M1-like phenotype through TLR4-associated signaling. The study combines an orthotopic cancer model with macrophage assays, providing a framework for connecting tumor burden, immune-cell polarization, inflammatory gene expression, and pathway perturbation.

• Anlotinib Hydrochloride: Translating Angiogenesis Biology

  2026-08-10

  An evidence-led perspective on how Anlotinib hydrochloride connects VEGFR2, PDGFRβ, and FGFR1 inhibition with endothelial phenotypes, ERK pathway control, assay strategy, and translational decision-making in cancer research.

• Imatinib hydrochloride: Applied Assay Workflows

  2026-08-09

  Build more informative kinase-inhibition studies with Imatinib hydrochloride by pairing dose–response data with pathway-proximal and orthogonal readouts. This workflow distinguishes v-Abl, c-Kit, and PDGFR dependence from nonspecific loss of viability while using the latest kinase–phosphatase findings to refine assay interpretation.

• Anlotinib VEGFR2 Inhibition: Preclinical Evidence

  2026-08-08

  The reference study established anlotinib as a potent, orally active VEGFR2 inhibitor that suppresses tumor angiogenesis across biochemical, cellular, ex vivo, and animal models. Its most important translational insight is the separation between highly sensitive endothelial responses and weaker direct effects on tumor-cell proliferation, supporting an angiogenesis-centered mechanism of action.

• Cannabidiol in Orofacial Inflammatory Pain: Mechanisms

  2026-08-07

  This 2026 Brain Research Bulletin study shows that cannabidiol (CBD) can reduce both nociceptive and pain-related affective abnormalities in mouse inflammatory pain models. Its central contribution is the integration of peripheral cannabinoid, trigeminal, cortical, endocannabinoid, and amygdala serotonergic measurements within a single experimental framework, while also identifying important limits for translation to receptor-specific therapies.

• Anlotinib Hydrochloride: Applied Use in Angiogenesis Assays

  2026-08-07

  Anlotinib hydrochloride accelerates anti-angiogenic research through ultra-selective, multi-target tyrosine kinase inhibition. Its low cytotoxicity and robust inhibition of VEGFR2, PDGFRβ, and FGFR1 position it as a superior choice for endothelial migration and tube formation assays, enabling more reproducible, high-sensitivity cancer research outcomes.

• Cabozantinib (XL184): Systems Biology Insights and Practical

  2026-08-06

  Explore the systems-level impact of Cabozantinib (XL184) on receptor tyrosine kinase signaling, with unique emphasis on translational phosphoproteomics, protocol optimization, and assay design for medullary thyroid and renal cell carcinoma research.

• Pentoxifylline Suppresses Hyperinflammation in Preterm Monoc

  2026-08-06

  Schüller et al. provide the first in vitro evidence that pentoxifylline (PTX) modulates LPS-induced hyperinflammatory responses in monocytes from preterm infants by downregulating key surface markers, cytokine production, and TLR4 signaling. These findings reveal age-dependent immunomodulatory effects with potential implications for adjunctive sepsis therapy in neonates.

• E-64d: Precision Cysteine Protease Inhibition in Cell Death

  2026-08-05

  E-64d enables targeted, membrane-permeable cysteine protease inhibition for dissecting calpain- and cathepsin-driven cell death pathways, including lysoptosis and apoptosis, in both cellular and animal models. This article details robust experimental workflows, troubleshooting strategies, and the translational impact of recent discoveries, empowering researchers to achieve reproducible, interpretable results with APExBIO's high-purity E-64d.

7980 records 2/532 page Previous Next 12345 下5页 Last page